ECSP18020055A - Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue - Google Patents

Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue

Info

Publication number
ECSP18020055A
ECSP18020055A ECIEPI201820055A ECPI201820055A ECSP18020055A EC SP18020055 A ECSP18020055 A EC SP18020055A EC IEPI201820055 A ECIEPI201820055 A EC IEPI201820055A EC PI201820055 A ECPI201820055 A EC PI201820055A EC SP18020055 A ECSP18020055 A EC SP18020055A
Authority
EC
Ecuador
Prior art keywords
inhibitors
compounds
mono
dengue
disustituted
Prior art date
Application number
ECIEPI201820055A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Arnaud Didier M Marchand
Dorothée Alice Marie-Eve Bardiot
Jean-Francois Bonfanti
Pierre Jean-Marie Bernard Raboisson
Tim Hugo Maria Jonckers
Original Assignee
Univ Leuven Kath
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Janssen Pharmaceuticals Inc filed Critical Univ Leuven Kath
Publication of ECSP18020055A publication Critical patent/ECSP18020055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos indólicos mono- o disustituidos, a métodos para prevenir o tratar infecciones virales por dengue utilizando dichos compuestos y también se refiere a dichos compuestos para su uso como una medicina, más preferentemente para su uso como una medicina para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como una medicina, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
ECIEPI201820055A 2015-09-16 2018-03-14 Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue ECSP18020055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15185523 2015-09-16
EP16163472 2016-04-01

Publications (1)

Publication Number Publication Date
ECSP18020055A true ECSP18020055A (es) 2018-04-30

Family

ID=56926217

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201820055A ECSP18020055A (es) 2015-09-16 2018-03-14 Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue

Country Status (30)

Country Link
US (1) US10765662B2 (es)
EP (1) EP3350162B1 (es)
JP (2) JP7050666B2 (es)
KR (1) KR102646174B1 (es)
CN (1) CN108473422B (es)
AU (1) AU2016324982B2 (es)
CA (1) CA2996979C (es)
CL (1) CL2018000696A1 (es)
CO (1) CO2018003471A2 (es)
CR (1) CR20180213A (es)
DK (1) DK3350162T3 (es)
EA (1) EA035663B1 (es)
EC (1) ECSP18020055A (es)
ES (1) ES2893298T3 (es)
HK (1) HK1257842A1 (es)
HR (1) HRP20211352T1 (es)
HU (1) HUE055870T2 (es)
IL (1) IL258043B (es)
JO (1) JOP20160198B1 (es)
LT (1) LT3350162T (es)
MA (1) MA42810A (es)
MX (1) MX2018003255A (es)
NI (1) NI201800039A (es)
PE (1) PE20181165A1 (es)
PH (1) PH12018500576A1 (es)
SI (1) SI3350162T1 (es)
TW (1) TWI758255B (es)
UA (1) UA122973C2 (es)
UY (1) UY36903A (es)
WO (1) WO2017046255A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) * 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA127863C2 (uk) 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
AU2017240076A1 (en) * 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110691773B (zh) 2017-05-22 2023-06-23 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
EP3630724B1 (en) 2017-05-22 2021-04-28 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177426B1 (en) * 1997-10-27 2001-01-23 Eli Lilly And Company Morpholino-N-ethyl ester prodrugs of indole sPLA2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
PE20081897A1 (es) * 2007-03-29 2009-02-09 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
BRPI0909985A2 (pt) 2008-06-03 2015-08-25 Siga Technologies Inc Composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada à mesma
CN102186833A (zh) * 2008-08-18 2011-09-14 耶鲁大学 Mif调节剂
ES2612731T3 (es) 2008-08-19 2017-05-18 Janssen Pharmaceutica Nv Antagonistas de receptores al frío de mentol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
AP2012006413A0 (en) 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
US20130023532A1 (en) * 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
SG11201606209PA (en) 2014-01-31 2016-08-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2721243T3 (es) 2014-10-01 2018-10-20
DK3201176T3 (en) 2014-10-01 2019-03-25 Janssen Pharmaceuticals Inc MONO OR DISUBSTITUTED INDEX DERIVATIVES AS INHIBITORS OF DENGUE VIRUS REPLICATION
TW201619130A (zh) * 2014-10-01 2016-06-01 健生醫藥公司 作為登革熱病毒複製抑制劑之單－或二－取代吲哚
JOP20150335B1 (ar) 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
RU2761212C2 (ru) 2015-11-03 2021-12-06 Зоэтис Сервисиз Ллс Полимерные композиты, полученные по способу золь-гель, и их применение
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CR20180495A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Deribados de indol sustituidos como inhibidores de replicación viral del dengue
AR108012A1 (es) 2016-03-31 2018-07-04 Takeda Pharmaceuticals Co Derivados de azaespiro[3,4]octan-6-ona como inhibidores de magl
EP3436018A4 (en) 2016-04-01 2019-11-13 Signal Pharmaceuticals, LLC SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF
KR102584280B1 (ko) 2016-04-01 2023-10-04 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
AU2017240076A1 (en) 2016-04-01 2018-08-09 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
CA3177398A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
KR102411744B1 (ko) 2016-04-01 2022-06-21 바스프 에스이 바이시클릭 화합물
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MY201207A (en) 2016-04-01 2024-02-09 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CN110691773B (zh) 2017-05-22 2023-06-23 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
EP3630724B1 (en) 2017-05-22 2021-04-28 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
JP2021181485A (ja) 2021-11-25
CN108473422B (zh) 2021-06-15
HRP20211352T1 (hr) 2022-02-04
NI201800039A (es) 2018-07-24
EP3350162B1 (en) 2021-07-14
CL2018000696A1 (es) 2018-07-06
LT3350162T (lt) 2021-09-27
CR20180213A (es) 2018-06-27
CN108473422A (zh) 2018-08-31
EA035663B1 (ru) 2020-07-23
CA2996979C (en) 2024-01-30
JOP20160198B1 (ar) 2022-03-14
AU2016324982A1 (en) 2018-03-15
KR20180052672A (ko) 2018-05-18
WO2017046255A1 (en) 2017-03-23
UY36903A (es) 2017-03-31
PE20181165A1 (es) 2018-07-19
ES2893298T3 (es) 2022-02-08
CO2018003471A2 (es) 2018-07-10
IL258043A (en) 2018-05-31
DK3350162T3 (da) 2021-10-04
JP7050666B2 (ja) 2022-04-08
MA42810A (fr) 2018-07-25
PH12018500576A1 (en) 2018-10-15
EP3350162A1 (en) 2018-07-25
TWI758255B (zh) 2022-03-21
HUE055870T2 (hu) 2021-12-28
TW201722913A (zh) 2017-07-01
EA201890722A1 (ru) 2018-09-28
US10765662B2 (en) 2020-09-08
HK1257842A1 (zh) 2019-11-01
JP2018528220A (ja) 2018-09-27
MX2018003255A (es) 2018-11-09
UA122973C2 (uk) 2021-01-27
KR102646174B1 (ko) 2024-03-08
AU2016324982B2 (en) 2021-04-15
CA2996979A1 (en) 2017-03-23
US20180256545A1 (en) 2018-09-13
IL258043B (en) 2021-08-31
SI3350162T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
NI201800040A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue